Literature DB >> 22531451

Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates.

Mauro Acchione1, Hyewon Kwon, Claudia M Jochheim, William M Atkins.   

Abstract

Antibody-drug conjugates (ADCs) with biotin as a model cargo tethered to IgG1 mAbs via different linkers and conjugation methods were prepared and tested for thermostability and ability to bind target antigen and Fc receptor. Most conjugates demonstrated decreased thermostability relative to unconjugated antibody, based on DSC, with carbohydrate and amine coupled ADCs showing the least effect compared with thiol coupled conjugates. A strong correlation between biotin-load and loss of stability is observed with thiol conjugation to one IgG scaffold, but the stability of a second IgG scaffold is relatively insensitive to biotin load. The same correlation for amine coupling was less significant. Binding of antibody to antigen and Fc receptor was investigated using surface plasmon resonance. None of the conjugates exhibited altered antigen affinity. Fc receptor FcγIIb (CD32b) interactions were investigated using captured antibody conjugate. Protein G and Protein A, known inhibitors of Fc receptor (FcR) binding to IgG, were also used to extend the analysis of the impact of conjugation on Fc receptor binding. H10NPEG4 was the only conjugate to show significant negative impact to FcR binding, which is likely due to higher biotin-load compared with the other ADCs. The ADC aHISNLC and aHISTPEG8 demonstrated some loss in affinity for FcR, but to much lower extent. The general insensitivity of target binding and effector function of the IgG1 platform to conjugation highlight their utility. The observed changes in thermostability require consideration for the choice of conjugation chemistry, depending on the system being pursued and particular application of the conjugate.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22531451      PMCID: PMC3355488          DOI: 10.4161/mabs.19449

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  31 in total

1.  The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein.

Authors:  A W Vermeer; W Norde
Journal:  Biophys J       Date:  2000-01       Impact factor: 4.033

2.  Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides.

Authors:  Michael M C Sun; Kevin S Beam; Charles G Cerveny; Kevin J Hamblett; Richard S Blackmore; Michael Y Torgov; Felicia G M Handley; Nathan C Ihle; Peter D Senter; Stephen C Alley
Journal:  Bioconjug Chem       Date:  2005 Sep-Oct       Impact factor: 4.774

3.  Heterogeneity of recombinant antibodies: linking structure to function.

Authors:  R J Harris
Journal:  Dev Biol (Basel)       Date:  2005

Review 4.  The immunoglobulin constant region contributes to affinity and specificity.

Authors:  Marcela Torres; Arturo Casadevall
Journal:  Trends Immunol       Date:  2008-01-10       Impact factor: 16.687

5.  A comparison between the sulfhydryl reductants tris(2-carboxyethyl)phosphine and dithiothreitol for use in protein biochemistry.

Authors:  E B Getz; M Xiao; T Chakrabarty; R Cooke; P R Selvin
Journal:  Anal Biochem       Date:  1999-08-15       Impact factor: 3.365

6.  Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97.

Authors:  Leia M Smith; Albina Nesterova; Stephen C Alley; Michael Y Torgov; Paul J Carter
Journal:  Mol Cancer Ther       Date:  2006-06       Impact factor: 6.261

7.  Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors.

Authors:  S Radaev; P D Sun
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

Review 8.  PEGylated antibodies and antibody fragments for improved therapy: a review.

Authors:  Andrew P Chapman
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

9.  Biological activities of polyethylene-glycol immunoglobulin conjugates. Resistance to enzymatic degradation.

Authors:  C Cunningham-Rundles; Z Zhuo; B Griffith; J Keenan
Journal:  J Immunol Methods       Date:  1992-08-10       Impact factor: 2.303

10.  Polymer modification of antibody to eliminate immune complex and Fc binding.

Authors:  W L Anderson; T B Tomasi
Journal:  J Immunol Methods       Date:  1988-04-22       Impact factor: 2.303

View more
  29 in total

Review 1.  Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.

Authors:  Satish K Singh; Donna L Luisi; Roger H Pak
Journal:  Pharm Res       Date:  2015-05-19       Impact factor: 4.200

Review 2.  Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.

Authors:  Jessica R McCombs; Shawn C Owen
Journal:  AAPS J       Date:  2015-01-22       Impact factor: 4.009

3.  Localized conformational interrogation of antibody and antibody-drug conjugates by site-specific carboxyl group footprinting.

Authors:  Lucy Yan Pan; Oscar Salas-Solano; John F Valliere-Douglass
Journal:  MAbs       Date:  2016-12-08       Impact factor: 5.857

4.  Quantitative collision-induced unfolding differentiates model antibody-drug conjugates.

Authors:  Yuwei Tian; Jennifer L Lippens; Chawita Netirojjanakul; Iain D G Campuzano; Brandon T Ruotolo
Journal:  Protein Sci       Date:  2018-12-22       Impact factor: 6.725

5.  A platform for constructing, evaluating, and screening bioconjugates on the yeast surface.

Authors:  James A Van Deventer; Doris N Le; Jessie Zhao; Haixing P Kehoe; Ryan L Kelly
Journal:  Protein Eng Des Sel       Date:  2016-11-01       Impact factor: 1.650

6.  Antibody Labeling with Fluorescent Dyes Using Magnetic Protein A and Protein G Beads.

Authors:  Nidhi Nath; Becky Godat; Marjeta Urh
Journal:  J Vis Exp       Date:  2016-09-15       Impact factor: 1.355

Review 7.  Challenges and new frontiers in analytical characterization of antibody-drug conjugates.

Authors:  Anil Wagh; Hangtian Song; Ming Zeng; Li Tao; Tapan K Das
Journal:  MAbs       Date:  2018-01-05       Impact factor: 5.857

Review 8.  Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Authors:  Paul Malik; Colin Phipps; Andrea Edginton; Jonathan Blay
Journal:  Pharm Res       Date:  2017-09-18       Impact factor: 4.200

Review 9.  Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.

Authors:  Delphine Vivier; Sai Kiran Sharma; Brian M Zeglis
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-14       Impact factor: 1.921

10.  Conjugation site heterogeneity causes variable electrostatic properties in Fc conjugates.

Authors:  Nicholas J Boylan; Wen Zhou; Robert J Proos; Thomas J Tolbert; Janet L Wolfe; Jennifer S Laurence
Journal:  Bioconjug Chem       Date:  2013-05-31       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.